Entero Therapeutics, Inc. (NASDAQ:GRDX) Sees Large Increase in Short Interest

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totaling 104,553 shares, an increase of 91.8% from the September 15th total of 54,523 shares. Based on an average daily trading volume, of 74,913 shares, the days-to-cover ratio is presently 1.4 days. Approximately 1.5% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Entero Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 29th.

Entero Therapeutics Stock Down 5.4%

Shares of NASDAQ GRDX traded down $0.24 during midday trading on Friday, hitting $4.22. The company had a trading volume of 107,475 shares, compared to its average volume of 115,811. Entero Therapeutics has a twelve month low of $1.87 and a twelve month high of $6.93. The business has a 50-day simple moving average of $3.64 and a two-hundred day simple moving average of $3.71. The firm has a market capitalization of $30.09 million, a price-to-earnings ratio of -2.22 and a beta of 1.69.

About Entero Therapeutics

Entero Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for gastrointestinal disorders. The company’s work is centered on treatments intended to address unmet needs in conditions involving inflammation, immune responses and intestinal health.

Its lead development program is latiglutenase, an oral enzyme therapy designed to break down immunogenic gluten fragments in the digestive tract. The program is being developed for celiac disease, an autoimmune disorder triggered by gluten exposure.